$FATE
Fate Therapeutics Inc

2016 Q4 Form 10-Q Financial Statement

#000156459016027939 Filed on November 07, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q4
Revenue $1.027M $1.026M $1.076M
YoY Change -4.55% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.450M $2.610M $2.560M
YoY Change -4.3% 11.06% 23.08%
% of Gross Profit
Research & Development $6.230M $6.804M $5.430M
YoY Change 14.73% 36.0% 40.31%
% of Gross Profit
Depreciation & Amortization $200.0K $220.0K $210.0K
YoY Change -4.76% 15.79% 61.54%
% of Gross Profit
Operating Expenses $8.681M $9.415M $7.988M
YoY Change 8.68% 28.03% 34.41%
Operating Profit -$8.389M
YoY Change 32.57%
Interest Expense -$290.0K $385.0K -$530.0K
YoY Change -45.28% -31.49% 82.76%
% of Operating Profit
Other Income/Expense, Net -$348.0K
YoY Change -37.63%
Pretax Income -$7.940M -$8.740M -$7.450M
YoY Change 6.58% 26.85% 19.58%
Income Tax
% Of Pretax Income
Net Earnings -$7.940M -$8.737M -$7.446M
YoY Change 6.63% 26.88% 19.46%
Net Earnings / Revenue -773.13% -851.56% -692.01%
Basic Earnings Per Share
Diluted Earnings Per Share -$213.1K -$272.4K -$259.4K
COMMON SHARES
Basic Shares Outstanding 34.15M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $92.10M $46.60M $64.80M
YoY Change 42.13% -36.08% 31.98%
Cash & Equivalents $88.61M $37.22M $64.81M
Short-Term Investments $3.500M $9.500M
Other Short-Term Assets $1.200M $800.0K $800.0K
YoY Change 50.0% 60.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $93.32M $47.40M $65.70M
YoY Change 42.04% -36.12% 31.77%
LONG-TERM ASSETS
Property, Plant & Equipment $1.579M $1.800M $2.200M
YoY Change -28.23% -14.29% 83.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $24.00K $100.0K $24.00K
YoY Change 0.0% 0.0% -76.0%
Total Long-Term Assets $1.725M $1.900M $2.258M
YoY Change -23.6% -13.64% 68.63%
TOTAL ASSETS
Total Short-Term Assets $93.32M $47.40M $65.70M
Total Long-Term Assets $1.725M $1.900M $2.258M
Total Assets $95.05M $49.30M $67.96M
YoY Change 39.86% -35.47% 32.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $934.0K $1.200M $996.0K
YoY Change -6.22% -7.69% 66.0%
Accrued Expenses $3.957M $3.300M $2.439M
YoY Change 62.24% 43.48% 6.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $8.187M $8.025M $7.550M
YoY Change 8.44% 23.46% 403.33%
Total Short-Term Liabilities $15.19M $14.68M $13.44M
YoY Change 12.99% 16.49% 192.2%
LONG-TERM LIABILITIES
Long-Term Debt $2.501M $4.610M $10.69M
YoY Change -76.6% -63.41% -40.95%
Other Long-Term Liabilities $4.200M $4.600M $5.800M
YoY Change -27.59% -25.81% 2800.0%
Total Long-Term Liabilities $2.501M $4.610M $10.69M
YoY Change -76.6% -75.48% -41.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.19M $14.68M $13.44M
Total Long-Term Liabilities $2.501M $4.610M $10.69M
Total Liabilities $17.69M $19.29M $24.13M
YoY Change -26.69% -38.57% 5.83%
SHAREHOLDERS EQUITY
Retained Earnings -$175.8M -$167.9M -$142.4M
YoY Change 23.5%
Common Stock $249.0M $193.3M $180.4M
YoY Change 38.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $73.15M $25.37M $38.04M
YoY Change
Total Liabilities & Shareholders Equity $95.05M $49.30M $67.96M
YoY Change 39.86% -35.48% 32.73%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q4
OPERATING ACTIVITIES
Net Income -$7.940M -$8.737M -$7.446M
YoY Change 6.63% 26.88% 19.46%
Depreciation, Depletion And Amortization $200.0K $220.0K $210.0K
YoY Change -4.76% 15.79% 61.54%
Cash From Operating Activities -$7.550M -$7.510M -$6.970M
YoY Change 8.32% 5.33% 13.33%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$40.00K -$180.0K
YoY Change -77.78% -93.85% -33.33%
Acquisitions
YoY Change
Other Investing Activities $6.020M $490.0K $0.00
YoY Change
Cash From Investing Activities $5.980M $460.0K -$180.0K
YoY Change -3422.22% -170.77% -33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 53.09M 8.280M -900.0K
YoY Change -5998.89% -1633.33% -109.0%
NET CHANGE
Cash From Operating Activities -7.550M -7.510M -6.970M
Cash From Investing Activities 5.980M 460.0K -180.0K
Cash From Financing Activities 53.09M 8.280M -900.0K
Net Change In Cash 51.52M 1.230M -8.050M
YoY Change -740.0% -114.78% -324.86%
FREE CASH FLOW
Cash From Operating Activities -$7.550M -$7.510M -$6.970M
Capital Expenditures -$40.00K -$40.00K -$180.0K
Free Cash Flow -$7.510M -$7.470M -$6.790M
YoY Change 10.6% 15.28% 15.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4610000
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10688000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
FATE
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34148154
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64809000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7550000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13441000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
58000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4934000
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
799000
CY2015Q4 fate Repurchase Liability For Unvested Equity Awards Current
RepurchaseLiabilityForUnvestedEquityAwardsCurrent
1000
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001434316
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q3 us-gaap Short Term Investments
ShortTermInvestments
9520000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2351000
us-gaap Contracts Revenue
ContractsRevenue
3375000
dei Amendment Flag
AmendmentFlag
false
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
996000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2439000
CY2015Q4 us-gaap Assets
Assets
67958000
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2105000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6328000
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
7354000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8389000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1676000
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-6886000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-348000
CY2016Q3 us-gaap Interest Expense
InterestExpense
385000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
CY2015Q3 us-gaap Interest Expense
InterestExpense
562000
CY2016Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-8000
us-gaap Net Income Loss
NetIncomeLoss
-25522000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-25519000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-22546000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29920075
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-558000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24404740
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1213000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-8737000
us-gaap Net Income Loss
NetIncomeLoss
-22546000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14678000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
54000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49295000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
25373000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
38038000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67958000
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
1180000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2401000
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
99000
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3355000
CY2016Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
8025000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
34000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167906000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142384000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q3 us-gaap Contracts Revenue
ContractsRevenue
1026000
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34148154
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28716570
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28716570
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
9415000
us-gaap Contracts Revenue
ContractsRevenue
1355000
dei Entity Registrant Name
EntityRegistrantName
FATE THERAPEUTICS INC
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28650356
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
477000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1920000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
132000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-288000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
759000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11427000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1320000
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
193242000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
180393000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1344000
us-gaap Interest Expense
InterestExpense
1683000
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q3 us-gaap Contracts Revenue
ContractsRevenue
1026000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-22272000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8745000
us-gaap Interest Expense
InterestExpense
1308000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6886000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32090174
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
678000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2365000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
111000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-158000
us-gaap Paid In Kind Interest
PaidInKindInterest
396000
us-gaap Paid In Kind Interest
PaidInKindInterest
494000
us-gaap Straight Line Rent
StraightLineRent
8000
fate Deferred Revenue Expense
DeferredRevenueExpense
1875000
fate Deferred Revenue Expense
DeferredRevenueExpense
-7911000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-81000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
417000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10092000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
167000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5003000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34148154
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6804000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2611000
us-gaap Straight Line Rent
StraightLineRent
16000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
846000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
19675000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
10000000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1320000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
385000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
32149000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10201000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4580000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5714000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
611000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4654000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
36503000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-27710000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23756000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49101000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72857000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p></div>
us-gaap Revenue Recognition Milestone Method Factors
RevenueRecognitionMilestoneMethodFactors
(i) persuasive evidence that an agreement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured.
CY2016Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4600000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4600000
CY2016Q3 fate Common Stock Issuable Upon Exercise Of Outstanding Options
CommonStockIssuableUponExerciseOfOutstandingOptions
4500000
fate Common Stock Issuable Upon Exercise Of Outstanding Options
CommonStockIssuableUponExerciseOfOutstandingOptions
4500000
CY2015Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3100000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3100000
CY2015Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
3000000
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
3000000
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
9517000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
9520000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2016Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2016Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2016Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1432000
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
993000
CY2016Q3 fate Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
643000
CY2015Q4 fate Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
446000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1268000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000000
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
37641
CY2016Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12740000
CY2015Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18454000
CY2016Q3 fate Debt Instrument Discount Non Current
DebtInstrumentDiscountNonCurrent
18000
CY2015Q4 fate Debt Instrument Discount Non Current
DebtInstrumentDiscountNonCurrent
77000
CY2016Q3 fate Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts
LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts
12722000
CY2015Q4 fate Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts
LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts
18377000
CY2016Q3 fate Long Term Debt Gross Current
LongTermDebtGrossCurrent
8112000
CY2015Q4 fate Long Term Debt Gross Current
LongTermDebtGrossCurrent
7689000
CY2016Q3 fate Debt Instrument Discount Current
DebtInstrumentDiscountCurrent
87000
CY2015Q4 fate Debt Instrument Discount Current
DebtInstrumentDiscountCurrent
139000
CY2016Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
400000
us-gaap Interest Expense Debt
InterestExpenseDebt
1300000
CY2015Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1700000
CY2016Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
100000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
783000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
574000

Files In Submission

Name View Source Status
0001564590-16-027939-index-headers.html Edgar Link pending
0001564590-16-027939-index.html Edgar Link pending
0001564590-16-027939.txt Edgar Link pending
0001564590-16-027939-xbrl.zip Edgar Link pending
fate-10q_20160930.htm Edgar Link pending
fate-20160930.xml Edgar Link completed
fate-20160930.xsd Edgar Link pending
fate-20160930_cal.xml Edgar Link unprocessable
fate-20160930_def.xml Edgar Link unprocessable
fate-20160930_lab.xml Edgar Link unprocessable
fate-20160930_pre.xml Edgar Link unprocessable
fate-ex311_7.htm Edgar Link pending
fate-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending